Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has granted non-statutory stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). One employee received 350,000 options at an exercise price of $9.34 per share, effective August 19, 2024. Another employee was granted 270,000 options at $8.43 per share, effective July 29, 2024. Both options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly over the next three years, subject to continued employment.
Fulcrum Therapeutics (Nasdaq: FULC), una compagnia biofarmaceutica in fase clinica, ha concesso opzioni su azioni non statutarie a due nuovi dipendenti nell'ambito del suo Piano di Incentivazione Azionaria 2022. Le concessioni sono state effettuate in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). Un dipendente ha ricevuto 350.000 opzioni a un prezzo di esercizio di $9,34 per azione, con effetto dal 19 agosto 2024. Un altro dipendente ha ricevuto 270.000 opzioni a $8,43 per azione, con effetto dal 29 luglio 2024. Entrambe le opzioni hanno un termine di dieci anni e maturano nel corso di quattro anni, con il 25% che matura al primo anniversario e il restante 75% che matura trimestralmente nei tre anni successivi, a condizione di continuare l'impiego.
Fulcrum Therapeutics (Nasdaq: FULC), una compañía biofarmacéutica en etapa clínica, ha otorgado opciones de acciones no estatutarias a dos nuevos empleados bajo su Plan de Incentivos de Acciones por Inducción 2022. Las concesiones se realizaron de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4). Un empleado recibió 350.000 opciones a un precio de ejercicio de $9.34 por acción, efectivas a partir del 19 de agosto de 2024. Otro empleado fue otorgado 270.000 opciones a $8.43 por acción, efectivas a partir del 29 de julio de 2024. Ambas opciones tienen un plazo de diez años y se consolidan durante cuatro años, con el 25% consolidándose en el primer aniversario y el 75% restante consolidándose trimestralmente durante los siguientes tres años, sujeto a la continuación del empleo.
Fulcrum Therapeutics (Nasdaq: FULC), 임상 단계의 생명공학 회사는 2022년 유인 주식 인센티브 계획에 따라 두 명의 신입 직원에게 비상 statutory 스톡 옵션을 부여했습니다. 이 부여는 Nasdaq 상장 규정 5635(c)(4)에 따라 이루어졌습니다. 한 직원은 350,000 옵션을 주당 $9.34의 행사 가격으로 부여 받았으며, 이는 2024년 8월 19일부터 효력이 발생합니다. 다른 직원은 270,000 옵션을 주당 $8.43의 가격으로 부여 받았으며, 이는 2024년 7월 29일부터 효력이 발생합니다. 두 옵션 모두 10년 기간을 가지며, 4년에 걸쳐 행사됩니다. 첫 번째 기념일에 25%가 행사되고, 나머지 75%는 다음 3년 동안 분기마다 행사됩니다. 이는 지속적인 고용을 조건으로 합니다.
Fulcrum Therapeutics (Nasdaq: FULC), une entreprise biopharmaceutique en phase clinique, a accordé des options d'achat d'actions non statutaires à deux nouveaux employés dans le cadre de son Plan d'Incitation d'Actions 2022. Les attributions ont été effectuées conformément à la Règle de Cotation Nasdaq 5635(c)(4). Un employé a reçu 350.000 options à un prix d'exercice de 9,34 $ par action, avec effet à compter du 19 août 2024. Un autre employé a reçu 270.000 options à 8,43 $ par action, avec effet à compter du 29 juillet 2024. Les deux options ont une durée de dix ans et s'acquièrent sur quatre ans, avec 25% acquises à la première année et les 75% restants acquises trimestriellement au cours des trois années suivantes, sous réserve de l'emploi continu.
Fulcrum Therapeutics (Nasdaq: FULC), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat zwei neuen Mitarbeitern nicht-statutäre Aktienoptionen im Rahmen seines Anreizprogramms für Stammaktien 2022 gewährt. Die Gewährungen erfolgten gemäß der Nasdaq-Listungsregel 5635(c)(4). Ein Mitarbeiter erhielt 350.000 Optionen zu einem Ausübungspreis von 9,34 $ pro Aktie, wirksam ab dem 19. August 2024. Ein anderer Mitarbeiter erhielt 270.000 Optionen zu 8,43 $ pro Aktie, wirksam ab dem 29. Juli 2024. Beide Optionen haben eine Laufzeit von zehn Jahren und vergüten über einen Zeitraum von vier Jahren, wobei 25% am ersten Jahrestag und die verbleibenden 75% vierteljährlich über die nächsten drei Jahre vergütet werden, vorbehaltlich einer fortgesetzten Anstellung.
- Fulcrum is attracting new talent with stock option incentives
- The company is complying with Nasdaq listing rules for employee compensation
- Potential dilution of existing shareholders' stakes due to new stock options
CAMBRIDGE, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum granted one new employee 350,000 options to purchase shares of the company’s common stock at an exercise price of
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
How many stock options did Fulcrum Therapeutics (FULC) grant to new employees?
What is the vesting schedule for the stock options granted by Fulcrum Therapeutics (FULC)?
What was the exercise price for the stock options granted by Fulcrum Therapeutics (FULC) on August 19, 2024?
Under which plan did Fulcrum Therapeutics (FULC) grant these stock options?
